Published in
Elsevier, Journal of Thoracic Oncology, 5(17), p. 718-723, 2022
DOI: 10.1016/j.jtho.2022.01.012
Links
Tools
Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial
Journal article published in 2022 by
Myung-Ju Ahn,
Byoung Chul Cho 
,
Xiaoling Ou,
Andrew Walding,
Angela W. Dymond,
Song Ren,
Mireille Cantarini,
Pasi A. Jänne
,
Xiaoling Ou,
Andrew Walding,
Angela W. Dymond,
Song Ren,
Mireille Cantarini,
Pasi A. Jänne
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 